Authors: Yu Hua Zhong Zhi Gang Zhong Zhou Zhou Zhen Yu Ma Meng Yao Qiu Fu Hua Peng Wei Xi Zhang
Publish Date: 2016/11/05
Volume: 38, Issue: 2, Pages: 271-277
Abstract
Patients with neuromyelitis optica NMO often have an accompanying autoimmune disease most commonly but not limited to Sjögren’s syndrome SS The aim of this study was to compare clinical and laboratory features between NMO patients with and without SS and to investigate the prognosis of NMO in patients with and without SS Twentythree NMO patients with SS and 42 NMO patients without SS were included Clinical and laboratory profiles were compared including annual relapse rate and time from onset of NMO to Expanded Disability Status Scale EDSS scores of 40 and 60 More NMO patients with SS than those without SS had antinuclear antibody antiSSA/Ro and antiSSB/La antibodies 913 vs 357 p 0001 870 vs 23 p 0001 and 348 vs 00 p 0001 respectively Serum immunoglobulins IgA IgM and IgG were markedly increased in NMO patients with SS in comparison with those without SS Annual relapse rate and the time from disease onset to an EDSS score of 40 and 60 were not significantly different between the two groups No differences between the two groups were found for the other parameters including AQP4 antibody status length of spinal cord lesion and brain lesions These results imply that NMO in SS more likely represents coexistence with SS rather than representing the result of direct central nervous system involvement in SS Autoimmune response appears to be more intense in the NMO group with SS but did not cause a more severe prognosis in comparison with the group without SS indicating that we should pay attention to the potential benefit of the antinuclear antibodies in NMOThis study was supported by the National Natural Science Foundation of China Grant Nos 81371260 and 30971026 and Guangdong Natural Science Foundation Grant No S2013010015600 The funders had no role in study design data collection and analysis decision to publish or preparation of the manuscript
Keywords: